🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

BETA DRUGS LIMITED BETA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://betadrugslimited.com
Company Profile ↓
₹2,304.80
+30.01% 1Y
Mkt Cap₹2,326.59 Cr
P/E54.85
P/B9.72
52W High₹2,366.80
52W Low₹1,030.30
Book Value₹242.48
EPS (TTM)₹42.02

Company Overview

Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.0%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 18.0%.

Consistent Profit Growth

Net profit has compounded at 10.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 19.2% CAGR over the past five years.

Healthy Margins

Operating margin of 15.2% supports profitability.

Recent Developments

  • Mar 2026 Revenue of ₹384.83 Cr (+6.2% YoY); net profit ₹41.48 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.2%, earnings -2.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 19.2%, profit CAGR 10.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:19.22%
1 Year:6.20%

Compounded Profit Growth

5 Years:10.53%
1 Year:-2.21%

Stock Price Performance

1 Year:+30.01%
6 Months:+40.89%
3 Months:+65.77%
1 Month:+25.56%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 95% of range
₹1,030.30 ₹2,366.80
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.92 · Neutral
Price Performance
1M+25.56%
3M+65.77%
6M+40.89%
1Y+30.01%
Valuation vs Sector

P/E of 54.85 is above the sector median of 39.70 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 19.2% over 5 years.
  • Profit CAGR of 10.5% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 54.9.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
54.85
Industry PE
39.70
Forward P/E est.
56.09
PEG Ratio
-
Book Value
₹242.48
Price to Book
9.72
P/S
6.16
EV/EBITDA
31.74
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
19.22%
Profit 5Y
10.53%
Revenue (YoY)
6.20%
Earnings (YoY)
-2.21%

Profitability & Returns

ROCE
17.98%
ROE
16.95%
ROA
8.37%
Profit Margin
10.78%
Op Margin
15.21%
Gross Margin
55.52%
EPS (Latest Qtr)
₹8.93
EPS (TTM)
₹42.02

Balance Sheet & Liquidity

Debt/Equity
0.60
Quick Ratio
2.41
Current Ratio
3.10
Debt
₹147.81 Cr
Total Assets
₹495.80 Cr
Current Assets
₹335.16 Cr
Working Capital
₹227.02 Cr

Ownership

Promoter Holding
0.00%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-8.96%

Financial Snapshot

Enterprise Value
₹2,326.59 Cr
Total Revenue (TTM)
₹384.83 Cr
EBITDA
₹86.86 Cr
Free Cash Flow
₹-16.20 Cr
Operating Cash Flow
₹37.29 Cr
Shares Outstanding
₹1.01 Cr
Gross Margin
55.52%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BETA BETA DRUGS LIMITED NSEPHARMA 2,304.80 54.85 ₹2,326.59 Cr 0.00% 17.98% 16.95% 19.22% 10.53%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue 88.29 Cr93.76 Cr103.39 Cr87.27 Cr93.96 Cr
Cost of Revenue 42.29 Cr43.96 Cr-36.04 Cr36.10 Cr
Gross Profit 46.00 Cr49.80 Cr-51.22 Cr57.87 Cr
Operating Expenses 30.79 Cr36.02 Cr82.09 Cr38.63 Cr44.99 Cr
Operating Income 15.22 Cr13.78 Cr17.06 Cr12.60 Cr12.88 Cr
EBITDA 17.07 Cr19.09 Cr21.30 Cr19.30 Cr20.57 Cr
Interest Expense 1.88 Cr3.29 Cr3.61 Cr4.43 Cr3.94 Cr
Pretax Income 11.96 Cr12.23 Cr16.44 Cr10.47 Cr11.83 Cr
Tax Provision 3.01 Cr3.20 Cr4.23 Cr1.95 Cr2.78 Cr
Net Income 8.95 Cr9.03 Cr12.22 Cr8.52 Cr9.05 Cr
Diluted EPS 9.319.4012.118.408.93

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 51.00 Cr66.00 Cr91.00 Cr116.00 Cr-227.11 Cr295.71 Cr362.36 Cr384.83 Cr
Cost of Revenue -----129.51 Cr181.20 Cr171.35 Cr171.18 Cr
Gross Profit -----97.61 Cr114.52 Cr191.00 Cr213.65 Cr
Operating Expenses 41.00 Cr54.00 Cr73.00 Cr91.00 Cr-54.58 Cr64.38 Cr128.91 Cr155.12 Cr
Operating Income 7.00 Cr9.00 Cr14.00 Cr18.00 Cr-43.03 Cr50.13 Cr62.09 Cr58.53 Cr
EBITDA 9.00 Cr12.00 Cr18.00 Cr25.00 Cr-53.75 Cr61.21 Cr76.47 Cr86.86 Cr
Interest Expense 1.00 Cr1.00 Cr3.00 Cr2.00 Cr-2.28 Cr2.68 Cr6.99 Cr15.31 Cr
Pretax Income 7.00 Cr8.00 Cr12.00 Cr16.00 Cr-41.06 Cr48.75 Cr56.97 Cr54.39 Cr
Tax Provision 7.00 L-16.00 L2.52 Cr4.32 Cr-10.34 Cr12.32 Cr14.55 Cr12.91 Cr
Net Income 7.00 Cr8.00 Cr9.00 Cr12.00 Cr-30.72 Cr36.44 Cr42.42 Cr41.48 Cr
Diluted EPS 7.438.849.3311.6024.5930.4337.9042.02-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 50.00 Cr83.00 Cr107.00 Cr118.00 Cr-198.42 Cr254.10 Cr436.23 Cr495.80 Cr
Current Assets -----127.68 Cr177.87 Cr331.08 Cr335.16 Cr
Cash & Equivalents -----19.16 Cr28.63 Cr147.02 Cr124.85 Cr
Inventory -----30.62 Cr49.81 Cr59.77 Cr74.46 Cr
Receivables -----62.72 Cr79.24 Cr102.58 Cr119.13 Cr
Total Liabilities -----75.54 Cr96.98 Cr239.14 Cr251.03 Cr
Current Liabilities -----63.02 Cr84.67 Cr102.73 Cr108.14 Cr
Long Term Debt -----6.97 Cr6.04 Cr126.99 Cr133.32 Cr
Total Debt 8.00 Cr20.00 Cr23.00 Cr17.00 Cr-20.33 Cr14.71 Cr138.06 Cr147.81 Cr
Total Equity 33.00 Cr41.00 Cr58.00 Cr69.00 Cr-122.88 Cr157.12 Cr197.10 Cr244.77 Cr
Shares Outstanding ----1.01 Cr1.01 Cr1.01 Cr1.01 Cr-

Cash Flows (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 17.00 Cr08.00 Cr19.00 Cr-23.38 Cr30.93 Cr36.17 Cr37.29 Cr
Investing Cash Flow -11.00 Cr-21.00 Cr-15.00 Cr-6.00 Cr--19.07 Cr-13.97 Cr-35.72 Cr-51.39 Cr
Financing Cash Flow 5.00 Cr12.00 Cr9.00 Cr-8.00 Cr--2.47 Cr-7.49 Cr117.94 Cr-8.07 Cr
Capital Expenditure -8.00 Cr-21.00 Cr-15.00 Cr-6.00 Cr--18.21 Cr-11.62 Cr-36.86 Cr-53.48 Cr
Free Cash Flow 9.00 Cr-21.00 Cr-7.00 Cr13.00 Cr-5.17 Cr19.31 Cr-68.59 L-16.20 Cr
Net Change in Cash 12.00 Cr-9.00 Cr2.00 Cr5.00 Cr-1.84 Cr9.47 Cr118.39 Cr-22.18 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -----43.0%38.7%52.7%55.5%
Operating Margin % 13.7%13.6%15.4%15.5%-18.9%17.0%17.1%15.2%
Net Margin % 13.7%12.1%9.9%10.3%-13.5%12.3%11.7%10.8%
ROE % 21.2%19.5%15.5%17.4%-25.0%23.2%21.5%16.9%
ROCE % -----31.8%29.6%18.6%15.1%

Shareholding Pattern

Insiders
0.00%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BETA

Yahoo Finance Mon, 10 Nov 2025

Beta Drugs Ltd (NSE:BETA) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst Margin ...

Beta Drugs Ltd (NSE:BETA) reports a 13% sales increase and improved EBITDA margins, despite facing challenges in gross profit margins and international business growth.

BETA — Frequently Asked Questions

What is the current share price of BETA DRUGS LIMITED (BETA)?

As of 2026-07-16 05:21 IST, BETA DRUGS LIMITED (BETA) trades at ₹2,304.80 on NSE. Its 52-week range is ₹1,030.30 to ₹2,366.80.

What is the market capitalisation of BETA?

BETA DRUGS LIMITED (BETA) has a market capitalisation of ₹2,326.59 Cr on NSE.

What is the P/E ratio of BETA?

BETA trades at a trailing price-to-earnings (P/E) ratio of 54.85. The industry average P/E is 39.70. Its price-to-book (P/B) ratio is 9.72.

What is the return on equity (ROE) of BETA?

BETA has a return on equity (ROE) of 16.95%. Its return on capital employed (ROCE) is 17.98%.

Is BETA a good stock to buy?

This page provides a data-driven analysis of BETA DRUGS LIMITED (BETA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space